Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

NCT01790308 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether combining the medication liraglutide with short-term insulin therapy helps people with type 2 diabetes maintain healthy blood sugar levels one year later.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 20–65 · all sexes

Timeline Started 2013-02 · est. completion 2015-12

What this study is testing ClinicalTrials.gov NCT01790308 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

Treatments tested

CSII Drug

continuous subcutaneous insulin infusion for 2\~4 weeks
Liraglutide Drug

CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months

Main thing measured	the percentage of the patients who maintain glucose control 1 year after short intensive therapy
Sponsor	Sun Yat-sen University
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01790308 ↗